A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study

被引:36
作者
Scott, Russell [1 ]
Morgan, Jerry [2 ]
Zimmer, Zachary [2 ]
Lam, Raymond L. H. [2 ]
O'Neill, Edward A. [2 ]
Kaufman, Keith D. [2 ]
Engel, Samuel S. [2 ]
Raji, Annaswamy [2 ]
机构
[1] Christchurch Sch Med, Lipid & Diabet Res Grp, Christchurch, New Zealand
[2] Merck & Co Inc, Kenilworth, NJ USA
关键词
clinical trial; dapagliflozin; sitagliptin; type; 2; diabetes; POOLED ANALYSIS; KIDNEY-DISEASE; INHIBITORS; EQUATION;
D O I
10.1111/dom.13473
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim Materials and Methods To compare the efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin with the sodium-glucose transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency. Patients with HbA1c >= 7.0 to <= 9.5% (>= 53 to <= 80 mmol/mol) and estimated glomerular filtration rate >= 60 to <90 mL/min/1.73m(2) on metformin (>= 1500 mg/d) +/- sulfonylurea were randomized to sitagliptin 100 mg (n = 307) or dapagliflozin 5 mg titrated to 10 mg (n = 306) once daily for 24 weeks. A longitudinal data analysis model was used to test the primary hypothesis that sitagliptin is non-inferior to dapagliflozin in reducing HbA1c at Week 24, with superiority to be tested if non-inferiority is met. NCT02532855. Results Conclusions Baseline mean HbA1c (% [mmol/mol]) was 7.7 (60.9) and 7.8 (61.2), and mean eGFR (mL/min/1.73m(2)) was 79.4 and 76.9 for the sitagliptin and dapagliflozin groups, respectively. After 24 weeks, the between-group difference in least squares mean (95% CI) changes from baseline in HbA1c was -0.15% (-0.26, -0.04) (-1.67 mmol/mol [-2.86, -0.48]), P = 0.006, meeting the prespecified criteria for declaring both non-inferiority and superiority of sitagliptin versus dapagliflozin. The HbA1c goal of <7% (<53 mmol/mol) was met by 43% (sitagliptin) and 27% (dapagliflozin) of patients. No meaningful between-group difference was observed in a pre-specified analysis of 2-hour incremental postprandial glucose excursion. A review of adverse events (AEs) was notable for a lower incidence of drug-related AEs with sitagliptin compared with dapagliflozin. In patients with type 2 diabetes, mild renal insufficiency and inadequate glycaemic control on metformin +/- sulfonylurea, sitagliptin treatment resulted in greater improvement in glycaemic control compared with dapagliflozin and was generally well tolerated.
引用
收藏
页码:2876 / 2884
页数:9
相关论文
共 50 条
[41]   Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial [J].
Mathieu, Chantal ;
Rudofsky, Gottfried ;
Phillip, Moshe ;
Araki, Eiichi ;
Lind, Marcus ;
Arya, Niki ;
Thoren, Fredrik ;
Scheerer, Markus F. ;
Iqbal, Nayyar ;
Dandona, Paresh .
DIABETES OBESITY & METABOLISM, 2020, 22 (09) :1516-1526
[42]   The efficacy and safety of berberine in combination with cinnamon supplementation in patients with type 2 diabetes: a randomized clinical trial [J].
Mansour, Asieh ;
Sajjadi-Jazi, Sayed Mahmoud ;
Gerami, Hadis ;
Khorasanian, Atie Sadat ;
Moalemzadeh, Behnam ;
Karimi, Sara ;
Afrakoti, Nima Mohamadi ;
Mofid, Vahid ;
Mohajeri-Tehrani, Mohammad Reza ;
Hekmatdoost, Azita .
EUROPEAN JOURNAL OF NUTRITION, 2025, 64 (02)
[43]   Long-term Efficacy and Safety of Sitagliptin in Elderly Patients with Type 2 Diabetes Mellitus [J].
Tada, Yuko ;
Kanazawa, Ippei ;
Notsu, Masakazu ;
Tanaka, Ken-ichiro ;
Kiyohara, Nobuaki ;
Sasaki, Motofumi ;
Sugimoto, Toshitsugu .
INTERNAL MEDICINE, 2016, 55 (10) :1275-1278
[44]   Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus [J].
Raz, I. ;
Hanefeld, M. ;
Xu, L. ;
Caria, C. ;
Williams-Herman, D. ;
Khatami, H. .
DIABETOLOGIA, 2006, 49 (11) :2564-2571
[45]   Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus [J].
I. Raz ;
M. Hanefeld ;
L. Xu ;
C. Caria ;
D. Williams-Herman ;
H. Khatami .
Diabetologia, 2006, 49 :2564-2571
[46]   Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial [J].
Araki, Eiichi ;
Onishi, Yukiko ;
Asano, Michiko ;
Kim, Hyosung ;
Yajima, Toshitaka .
DIABETES OBESITY & METABOLISM, 2017, 19 (04) :562-570
[47]   Efficacy and safety of sitagliptin added to metformin and insulin compared with voglibose in patients with newly diagnosed type 2 diabetes [J].
Shi, Chunhong ;
Zhang, Ru ;
Bai, Ran ;
Liu, Dan ;
Wang, Yongbo ;
Zhang, Xueyang ;
Wang, Hao ;
Du, Jianling .
CLINICS, 2019, 74
[48]   Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial [J].
Han, Kyung-Ah ;
Chon, Suk ;
Chung, Choon Hee ;
Lim, Soo ;
Lee, Kwan-Woo ;
Baik, SeiHyun ;
Jung, Chang Hee ;
Kim, Dong-Sun ;
Park, Kyong Soo ;
Yoon, Kun-Ho ;
Lee, In-Kyu ;
Cha, Bong-Soo ;
Sakatani, Taishi ;
Park, Sumi ;
Lee, Moon-Kyu .
DIABETES OBESITY & METABOLISM, 2018, 20 (10) :2408-2415
[49]   Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial [J].
Kaku, K. ;
Inoue, S. ;
Matsuoka, O. ;
Kiyosue, A. ;
Azuma, H. ;
Hayashi, N. ;
Tokudome, T. ;
Langkilde, A. M. ;
Parikh, S. .
DIABETES OBESITY & METABOLISM, 2013, 15 (05) :432-440
[50]   DAPA-RWE: a retrospective multicenter study comparing dapagliflozin and sitagliptin in patients with Type 2 diabetes treated under routine clinical practice in Spain [J].
Morales, Cristobal ;
Bellido, Virginia ;
Tejera, Cristina ;
Goni, Fernando ;
Palomares, Rafael ;
Sevillano, Cristina ;
Bellido, Diego ;
Soto, Alfonso ;
Mangas, Miguel Angel ;
Botana, Manuel A. ;
Caballero, Irene .
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (10) :815-821